Surgical Oncology (Complex General Surgical Oncology) — Specialty Profile

Subspecialty fellowship of General Surgery.

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: CGSO, surgical oncology, surg onc. A fellowship you enter after completing a General Surgery residency, reached through general surgery rather than straight from medical school. Organ systems: the solid-tumor abdomen and beyond, covering liver, pancreas, stomach, peritoneum, soft tissue, skin, and endocrine glands.

The 30-second version

Surgical oncology is the field of the biggest, hardest cancer operations, and of the tumor board that decides whether an operation is even the right move. A complex general surgical oncologist removes tumors that most general surgeons refer out: the Whipple for pancreatic cancer, the liver resection, the total gastrectomy, the retroperitoneal sarcoma, the cytoreduction-plus-heated-chemo (HIPEC) for a belly full of cancer. But the operation is only half the job. The other half is thinking about cancer as a whole disease, sitting at multidisciplinary tumor board with medical oncology, radiation oncology, pathology, and radiology and reasoning about sequencing, staging, and whether surgery helps this patient at all. It's a field organized around depth in one terrible disease, not breadth or speed.

The paradox defines the field: you can train for 7 to 9 years after medical school to do the most technically demanding operations in general surgery, and then earn less than a busy community general surgeon who stopped years earlier. The draw is genuinely not the money. It's the operations, the intellectual depth of oncology, and the mission.

Quick dashboard (details and sources below)
Training after med school General Surgery residency (5, often +1–3 research yrs) + CGSO fellowship (2) = 7+ yrs after med school (commonly 8–10)
Total from college start ~15–17 years (4 undergrad + 4 med school + 5 GS residency + often research yr(s) + 2 fellowship)
Competitiveness (as a surgical fellowship) Competitive academic fellowship — ~69% of applicants match; positions fill 100% ⟳
Typical full-time pay ~$450,000–$600,000 total comp (estimated; no clean CGSO-specific survey) ⟳
Pay range (structure) Academic start $250k–$350k · mid-career clustered near or below the general-surgery median ($530k) · senior/high-volume $700k+ ⟳
Lifestyle Long, heavy operative days — but mostly elective and scheduled, more controllable than trauma/transplant
Burnout No current figure is published for the field; the only specialty-specific study is Shanafelt 2008, at ~28–32% ⟳
% women ~38.6% of CGSO fellows (2013–2021 pooled) ⟳
DO / IMG accessibility Low DO (~8% of matched), modest IMG (~14% of matched, and a lower match rate) ⟳

What they actually do

Complex general surgical oncologists operate on solid cancers that require more volume, more infrastructure, and more technical range than a general surgeon typically carries: hepato-pancreato-biliary (HPB) cancers, complex gastric and GI resections, peritoneal-surface disease treated with cytoreduction and HIPEC, retroperitoneal and soft-tissue sarcoma, complex melanoma and regional nodal disease, and endocrine cancers (with breast at some centers). These are among the longest operations in general surgery: a major HPB case or a cytoreduction and HIPEC can run 6 to 12+ hours. The work is overwhelmingly planned: patients are worked up, staged, and discussed before a date is ever set.

But the defining skill is multidisciplinary cancer reasoning as much as the hands, the ability to sit at tumor board and think about a cancer across surgery, chemotherapy, radiation, pathology, and genetics, and to know when not operating is the right call. The field's own leaders define a surgical oncologist partly as "a surgeon who can speak the language of multidisciplinary cancer management."1 Around the OR, the week braids outpatient clinic (new-cancer consults, surveillance, survivorship), tumor board, and, because the field is largely academic, research, teaching, and a heavy load of cancer-staging documentation.

Representative operations: pancreaticoduodenectomy (Whipple) · hepatectomy / liver resection · total and subtotal gastrectomy · cytoreductive surgery with HIPEC · retroperitoneal and soft-tissue sarcoma resection · complex melanoma excision with sentinel-node and regional nodal dissection · adrenalectomy and other endocrine cancer surgery · complex GI resections · multidisciplinary tumor-board leadership.

A day in the life: An OR day is often one or two enormous cases rather than a busy churn of small ones, so you scrub in the morning and may not finish until evening, standing for hours on a single reconstruction. A clinic day is new-cancer consults (delivering hard news, planning), post-op checks, and years-long surveillance visits. Woven through the week is tumor board, where each patient is debated by the whole cancer team. Emergent add-ons still happen, whether bleeding, obstruction, or a post-op complication, and general-surgery call is common early in an academic career. But the base rhythm is OR blocks, clinic, and conference: long days you can largely see coming.2

The training path & time to completion

MD/DO (4 yrs) → General Surgery residency (5 yrs clinical, frequently + 1–3 dedicated research years) → CGSO fellowship (2 yrs, matched via the SSO/NRMP Specialties Matching Service) → board certification in Complex General Surgical Oncology from the American Board of Surgery (ABS).3 You reach surgical oncology through general surgery. There is no direct path from medical school. That means the clock is long: you first become a fully trained general surgeon, then subspecialize.

  • Total after medical school: ~7 years minimum (5 GS + 2 CGSO), but commonly 8–10 years because most competitive applicants take 1–3 protected research/lab years during residency. This is one of the most research-heavy pipelines in surgery.34
  • Fellowship: 2 years / 96 weeks of ACGME-accredited training (48 weeks of full-time clinical activity per year).3
  • Board: ABS certification in CGSO requires prior ABS General Surgery certification, completion of the ACGME fellowship, an acceptable operative-experience report, and passing both a Qualifying Exam (QE) and a Certifying Exam (CE).3
  • Total from the start of college: roughly 15–17 years (4 undergrad + 4 med school + 5 GS residency + often 1–2 research years + 2 fellowship).

A note on history: "surgical oncologist" was more a self-description than a certified title until recently. The ABS approved the CGSO certificate around 2011, ACGME began accrediting programs, and the first board certifications through ACGME-accredited fellowships came in 2014, transitioning the older, decades-old Society of Surgical Oncology (SSO) fellowships into formal board recognition.5 ⟳

How competitive is it?

Surgical oncology is a competitive academic fellowship, but it's a different kind of competitive from a base-residency match, so read the numbers with that framing.

In the 2026 SSO/NRMP Specialties Matching Service cycle (the CGSO match), there were 41 programs offering 77 positions, and all 77 filled (100%). But 111 applicants competed for those 77 spots, so roughly 69% of applicants matched and ~31% went unmatched.6 ⟳ The programs almost never leave a seat open (historically only two unfilled positions across 2014–2021); the competition is applicant-side.67

What that means for you:

  • The pool is small, elite, and research-heavy. Nearly all matched fellows head to academic/NCI-designated centers, and dedicated research years plus a substantial publication record are effectively expected at competitive programs.47
  • US-MD applicants dominate and match best. In 2026, of 77 filled positions, 56 went to US MD grads, 11 to IMGs, 6 to US DO grads and 4 to Canadian graduates.6 Longitudinal data (2014–2021) put the US-allopathic match rate at 84% vs 55% for non-US allopathic applicants in 2021, a gap that has narrowed over the period.7 ⟳
  • The overall match rate has risen. 54% (2014) to 74% (2021), as programs grew and total applicants dipped, partly because complex-cancer surgeons increasingly train through other fellowships (HPB, colorectal, breast, endocrine) instead of CGSO.7

The honest read: getting into CGSO is a long game that starts in residency, built on research and academic pedigree, but the applicant numbers at the door are not the hard part. The harder question is upstream: you first have to match and finish one of the most demanding residencies in medicine.

Compensation — the robust version

This is the section to slow down for, because surgical oncology's pay story is genuinely unusual, and it's the part a premed would never pick up from a list. A caveat on sources first: there is no clean, single authoritative national number for CGSO. The big surveys (Doximity, Medscape) fold it into "General Surgery" and don't break it out, so every SurgOnc-specific dollar figure here is an estimate, and general surgery is the most defensible benchmark.89

National number. Depending on source, a surgical oncologist lands somewhere around $450,000–$600,000 total compensation, clustered near the general-surgery median or a bit below it, despite the extra fellowship years. Reference points: a crowdsourced tracker puts "oncologic surgeon" total comp at ~$523,000 (small self-reported n); an industry guide cites a broad $400,000–$700,000 band; and General Surgery itself runs ~$434,000 (Medscape) to ~$482,574 (Doximity) to a $530,000 median (SalaryDr panel, n=128).89101112 ⟳

The spread (using General Surgery as proxy, SalaryDr's 128-physician panel, 2026): 10th pct $400,000 · 25th $480,000 · median $530,000 · 75th $630,000 · 90th $800,000, with extreme top submissions to $1.2M.12 For surgical oncology specifically the realistic band is compressed toward the lower-middle because the field skews academic: junior academic starts around $250,000–$350,000, senior/leadership academic clears $500,000+, and high-volume private/community can reach ~$700,000.1113 ⟳

Starting vs. experienced. Academic assistant-professor start ~$250k–$350k; private/community start ~$350k–$450k; established senior academic $500k+; experienced high-volume private up to ~$700k.1113 For reference, general surgery's community experience curve runs ~$449k (0–2 yrs) to ~$660k (16+ yrs)12, and surgical oncologists, being disproportionately academic, tend to lag those community numbers at every stage.

Academic vs. private, and why it drags pay down. Surgical oncology is overwhelmingly academic: complex resections concentrate at high-volume tertiary/NCI-designated centers, and CGSO fellowships feed university faculty tracks. Academic jobs pay a lower base with protected (often unpaid) research/admin time; the institution captures much of the surgical revenue.13 Because academic jobs dominate and pay less, the field-wide average is structurally pulled down.

Geography works against you here. There's no CGSO-specific geographic table, but the general pattern, in which Midwest, South, and lower-cost metros pay more while coastal academic hubs (Boston, NYC, SF, LA) pay less in raw comp, is reinforced for surgical oncology, because the NCI-designated centers where this work lives (MD Anderson, MSK, Hopkins, City of Hope) cluster in exactly those high-cost, low-comp metros.812 Less geographic flexibility, and the flexibility you do have points toward lower pay.

The RVU trap. Practice is predominantly hospital-/university-employed (salary + wRVU productivity bonus). A Whipple that eats a full day generates relatively few wRVUs per hour compared with a general surgeon doing several lap choles or hernias in the same time, and that's before the extensive uncompensated tumor-board, staging, and long oncologic-follow-up work. In pure RVU models, complex cancer surgery is structurally penalized per hour.13

The pay-vs-complexity paradox (the honest core). This field is the textbook case of "more training + harder cases ≠ more money." Practitioner consensus is that surgical oncology carries the lowest median salaries among the general-surgery subspecialties, including general surgery itself; one trauma surgeon reported private offers worth 3× his surgical-oncology comp.13 And there's peer-reviewed backing: a study of lifetime revenue across surgical specialties found that, once the extra fellowship/opportunity cost is counted, surgical oncology nets ~$1.7 million LESS over a 30-year career than general surgery, roughly four years of lost earnings, concluding that "not all surgical subspecialization leads to higher lifetime revenue."14 For contrast, SalaryDr's top-earning GS subspecialties (Breast ~$846k, Bariatric ~$782k, Trauma ~$624k) all sit above the SurgOnc band.12 The draw is not financial. It's the operations, the disease, and the academic mission.

Benchmarks & caveats. BLS lists "Surgeons, All Other" at a $373,930 mean (May 2025), a known undercount that pools every surgical specialty BLS does not break out into one residual code; use it as a floor rather than a target.9 MGMA publishes a General Surgery: Surgical Oncology median, but it sits behind a paywall; MGMA general-surgery medians generally run ~$450k–$550k.15 The SSO does not publish a public standalone salary survey.13 ⟳

Lifestyle & the scheduled-marathon bargain

The single most-cited feature of surgical oncology, relative to other heavy surgical fields: the work is planned. Unlike trauma, transplant, or emergency general surgery, these are big elective operations: patients are worked up, staged at tumor board, and operated on a scheduled date. That makes the days long and heavy but more controllable than emergency-driven fields, where the pager sets your calendar.2

The trade is the marathon itself. There's no clean surgical-oncology-specific hours dataset, but attending general surgeons run roughly 60–66 hrs/week, and complex-oncology practice sits at or above that given case length, clinic, tumor board, and academic duties.16 Emergent add-ons (post-op bleeding, obstruction) still happen, and general-surgery call is common early in an academic career. Schedule control is moderate, better than trauma, transplant, or EGS and worse than a lifestyle-optimized community practice or an endocrine- and breast-heavy elective niche, and it improves with seniority and with tilting toward a lower-acuity sub-focus.2

Lifestyle rating: 2/5. Long, physically demanding operative days and heavy academic load, softened by the fact that most of it is scheduled rather than emergent. The predictability is real; the volume of hours is also real.

Wellbeing — the part to take seriously

There is no current burnout figure for this field, and the one that exists is from 2008. Neither of the cross-specialty instruments breaks out surgical oncology, so nothing current is published for the field itself. For scale, the AMA's 2025 Organizational Biopsy puts parent general surgery at 43.8% against a 41.9% all-physician average. The only specialty-specific study is Tait Shanafelt's in Annals of Surgical Oncology, which put burnout at roughly 28–32% of surgical oncologists — below many high-burnout fields and below emergency-driven surgery, plausibly because the work is meaningful, mission-aligned, and more scheduled. That was eighteen years ago, before the EHR era that drives most of what physicians now report as burnout.17 When burnout did appear, it showed up as loss of enthusiasm, depersonalization, and a sense that the work lacked meaning, and it was "the single greatest predictor of dissatisfaction with career and specialty choice." (Caveat: this data is older, so treat the percentages as directional rather than current.) ⟳

The "delayed gratification" trap. Shanafelt specifically warns against the surgeon mindset that treats residency as a survival period on the assumption that life improves after, when early-attending demands tend to perpetuate the same unsustainable patterns. That warning bites harder in surgical oncology than almost anywhere, because the training tail is so long: you can spend a decade telling yourself it gets better once you finish.17

The emotional weight is specific to cancer. Three things distinguish this from general surgery: you often follow patients for years through surveillance, recurrence, and sometimes death, so losses become personal; some operations are palliative or recur despite a technically perfect resection, so you live inside the limits of what surgery can fix;18 and the cumulative grief of oncology, described by clinicians as "the price of caring deeply," is something training rarely prepares you for.19

Satisfaction & longevity. Nobody has published a would-choose-again rate by specialty since about 2019, so there is no figure to give here and none is asserted. The consistent theme in the field's own literature is high meaning, and surgeons frame the work as a privilege and a calling, which appears to buffer the strain. It's physically demanding and emotionally cumulative, but the elective, scheduled, academic nature makes it more sustainable long-term than emergency-heavy surgery; many taper operative complexity later and lean into clinic, research, mentorship, or administration.17

Who's in the field (demographics)

Best source is CGSO fellowship-trainee data (ACGME 2013–2021, Ann Surg Oncol 2023), which is more specific than practicing-workforce estimates.

  • Women: ~38.6% of CGSO fellows (2013–2021 pooled), below the ~45.6% across all ACGME fellowships, and notably flat: there was no statistically significant increase in female representation over 2013–2021, even as general surgery residency and other surgical fellowships gained.20 ⟳
  • URiM: ~8.9% of CGSO fellows, below the all-trainee pool (~12.8%) and general surgery residency (~13.1%), and also without significant gain over the period.20 ⟳
  • DO: a small minority, at ~8% (6 of 77 matched positions in 2026).6 ⟳
  • IMG: ~14% (11 of 77 matched in 2026), though IMGs match at lower rates than US MDs (non-US allopathic 55% vs US allopathic 84% in 2021).67 ⟳

(No reliable Asian-vs-White or year-by-year gender breakdown was located beyond the pooled 2013–2021 figures.)

Culture, personality & the online stereotypes

Who gravitates here: academically driven, technically ambitious surgeons who want the most complex oncologic operations and are genuinely drawn to multidisciplinary, tumor-board medicine, thinking about a cancer across surgery, chemo, radiation, pathology, and genetics rather than just the cut. Research-minded people (many do dedicated research years); people who value intellectual depth in a disease and long-term patient relationships over sheer procedural volume or maximal pay. Plenty of surgical oncologists don't fit that mold, but the field's own leaders describe it as fundamentally about "speaking the language of multidisciplinary cancer management." As always, plenty of people in the field do not fit any single mold.1

The online reputation (labeled as reputation rather than fact, each with an unfair edge):

  • "Elite and academic, the top of the general-surgery prestige ladder." Real as a perception; matched fellows do skew toward strong residents at big-name programs. But "prestige" flattens a field people choose for the disease rather than the label, and the long road punishes anyone chasing the label alone.
  • "You train forever to earn less than a community general surgeon." The sharpest recurring line online, and, unusually for a stereotype, it has genuine substance on the pay-vs-training math (see Compensation). It's still a caricature: it erases how worth-it many find the work, and the community/hybrid practices that do pay well.
  • "A strong general surgeon already does cancer surgery, so why bother?" A real debate rather than a dunk. The fellowship earns its keep specifically if you want HPB, HIPEC, sarcoma, or a purely academic tertiary-center career.
  • "What even is a surgical oncologist anymore?" Not an insult but the field's own open question, as breast, HPB, colorectal, and endocrine surgeons increasingly train through their own fellowships.

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums the dominant thread is pay-versus-training, and commenters repeatedly note that CGSO adds ~2 years plus research for a subspecialty that often nets less over a career than staying a general surgeon, with the frequent takeaway to do it for the operations and the mission, not the money. Alongside that: deep respect for the technical ceiling (HPB and cytoreduction/HIPEC cited as some of the hardest operations in general surgery); a recurring point that a strong general surgeon already does a lot of cancer surgery, so the fellowship pays off mainly for a specific sub-focus or an academic career; ongoing debate about the value of the CGSO boards given hyperspecialization into HPB/colorectal/breast/endocrine tracks; and consistent advice that "surgical oncology lifestyle" varies enormously by sub-focus and setting, and that applicants underestimate the emotional load of cancer care.

Voices from the field. Paraphrased from public writing, with links to the originals:

  • Tait Shanafelt, MD (Mayo) argues the field can be sustainable and deeply satisfying, but only if surgeons proactively identify their values, build the practice around them, and reject the "survive training, then it gets better" myth; he frames burnout as the top predictor of career-choice regret.17
  • Douglas Tyler, MD, in his 2022 SSO Presidential Address, defines the modern surgical oncologist as "a surgeon who specializes in an area of cancer care and can speak the language of multidisciplinary cancer management," and candidly documents the field fragmenting into hyperspecialties and declining CGSO applications.1
  • A surgeon writing on the emotional core of cancer care reframes grief as evidence of real connection rather than weakness, "the price of caring deeply," and notes training doesn't prepare clinicians for the cumulative heartbreak of oncology.19
  • Baimas-George et al. provide the empirical backbone of the online "train more, earn less" narrative: adjusted for the extra fellowship years, surgical oncology nets ~$1.7M less over a 30-year career than general surgery. The projection runs off MGMA's 2015 average salaries, so read it as a structural argument about opportunity cost rather than a current dollar figure.14

Why people choose it / why people leave

Why choose it: you do the most complex oncologic operations in general surgery (HPB, HIPEC/cytoreduction, sarcoma, gastric, endocrine) and the technical mastery they demand · you're energized by multidisciplinary, tumor-board medicine, reasoning about cancer across modalities rather than just cutting · you value long-term patient relationships and find meaning in high-stakes, sometimes non-curative care · you want an academic/tertiary-center career with research, teaching, and mentorship · the work is mostly scheduled and arguably more sustainable long-term than trauma/transplant/EGS.

Why leave or avoid it: very long training (7–9 years post-MD, often more) before real attending income · pay that often nets below high-volume community general surgery, a documented lifetime-earnings gap · heavy operative days plus the cumulative emotional weight of cancer loss and grief · concentration in academic settings and big referral cities, so less geographic and practice flexibility than plain general surgery · if you love the OR but not the disease, a general surgeon already does substantial cancer work.

Best fit if: you genuinely love oncology as a field, meaning the biology, the multidisciplinary chess game, and the relationships, and want to operate at the top of surgical complexity · you're academically/research-driven and want a tertiary-center career · you can tolerate a long training tail and aren't optimizing for maximum or earliest income · you find meaning (not just drain) in caring for patients you may not be able to cure.

Not for you if: you need to start earning as soon as possible or want the highest lifetime return on your training years · you want geographic flexibility, a portable community practice, or a predictable elective-only lifestyle early · the emotional weight of cancer, recurrence, and death would erode rather than motivate you · you're chasing the "elite" label without loving the actual disease and the operations, because the long road punishes that.

The FLI angle — Surgical Oncology for first-gen, low-income & immigrant students

This is a field where the FLI calculus is unusually sharp, because its central trade, the most meaningful and most complex work in exchange for the longest wait and a lower ceiling than the obvious alternative, hits FLI students hardest. Name it squarely.

The genuine draw:

  • Top-tier surgical training and unusually high meaning. The most complex operations, an intellectual multidisciplinary field, and work that matters at the deepest human level. For an FLI student motivated by mastery and mission, few fields rival it.

The honest catch, and it's a real one:

  • The longest income deferral in general surgery. 5 years of residency + 2 of fellowship = 7 years minimum, and 8–9 with the near-standard research years, before real attending income.2 For someone with no family safety net who may be supporting others now, that delay is the single heaviest FLI-specific consideration.
  • Pay is largely academic and often below high-volume community general surgery. This is the crux, and it's the rare case where doing more training can leave you with less: an FLI student who completes the extra fellowship years can net ~$1.7M less over a career than if they'd stopped at general surgery and worked a busy community practice.14 You trade money and time for the operations and the academic life.
  • Less geographic/practice flexibility. The work concentrates at academic and NCI-designated centers in bigger, higher-cost cities, narrower than the go-anywhere portability of general surgery, which can matter if family or immigration status ties you to a place.
  • Access barriers stack early. The pipeline rewards dedicated research years and academic pedigree built during residency, resources and mentorship that are exactly what FLI students most often lack going in.

How to think about it (FLI-honest): if you need to earn sooner or want the maximum financial return on your training, general surgery, or a higher-paying subspecialty like breast or bariatric, is the more FLI-pragmatic call, and a general surgeon already does meaningful cancer work. Surgical oncology is a values choice: it rewards people who specifically want the complex operations and the academic-oncology life enough to accept a longer wait and a lower ceiling. That's a completely legitimate choice, but make it with eyes open about the money and the years, not for the "elite" label alone.

Bottom line: the best surgical training and some of the deepest meaning in medicine, bought at the cost of the longest income deferral in general surgery and pay that trails the community-general-surgery alternative. A real tradeoff for anyone who needs to earn, worth it for the right person and expensive for the wrong reason.

Subspecialties & sub-focus areas

CGSO is itself a fellowship, but surgical oncologists further concentrate, and, increasingly, complex-cancer surgeons train through these instead of CGSO, part of the field's ongoing fragmentation.1

  • Hepato-Pancreato-Biliary (HPB). Liver, pancreas (Whipple), and biliary cancers; some of the longest, highest-complexity abdominal operations; trained via CGSO or a dedicated HPB fellowship.21
  • Peritoneal Surface Malignancy / HIPEC. Cytoreductive surgery plus heated intraperitoneal chemotherapy for appendiceal, colorectal, and ovarian peritoneal spread; marathon cases at highly specialized centers.
  • Sarcoma / Melanoma. Soft-tissue and retroperitoneal sarcoma, complex melanoma and regional nodal disease; heavy multidisciplinary coordination.
  • GI / Gastric / Colorectal cancer surgery. Complex gastric and GI resections; overlaps heavily with colorectal surgery, which many now enter through a colorectal fellowship instead.
  • Endocrine surgical oncology. Thyroid, parathyroid, adrenal cancers; largely elective, more favorable lifestyle; increasingly its own endocrine fellowship track.
  • Breast surgical oncology (overlap). Breast cancer surgery; predominantly elective, clinic-heavy, more controllable hours, and among the highest-paid GS subspecialties; now largely a distinct breast fellowship, though historically core surgical oncology.

Fun facts

  • Complex General Surgical Oncology only became a formally ABS-boarded subspecialty around 2011–2014. Before that, "surgical oncologist" was more a self-description than a certified title.5
  • HIPEC. Heated chemotherapy bathed directly into the abdomen after tumor cytoreduction, makes peritoneal-surface surgery one of the few places a surgeon literally delivers chemo in the OR.
  • It may be one of the only surgical fields where doing more training can net you less lifetime money than not doing it, a rare inversion of the usual "subspecialize to earn more" rule.14
  • The field is fragmenting: breast, HPB, colorectal, and endocrine cancer surgeons increasingly train through their own fellowships, prompting the SSO to publicly wrestle with "what even is a surgical oncologist?"1
  • Despite brutal hours and cancer's emotional load, surgical oncologists reported lower burnout (~28–32%) than many emergency-driven specialties in the one study that has ever measured the field, published in 2008.17
  • Tumor board. Where surgeons, oncologists, radiologists, and pathologists debate each case together, is central enough that the SSO defines the specialty partly by the ability to "speak the language" of it.1

Sources

Footnotes

  1. Douglas Tyler, MD — 2022 SSO Presidential Address, "What is a Surgical Oncologist?" — field identity, multidisciplinary "language," fragmentation into hyperspecialties, declining CGSO applications. Annals of Surgical Oncology (2022). https://link.springer.com/article/10.1245/s10434-022-11770-3 ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Lifestyle/scheduled-elective nature, hours, schedule control, long training tail. MSKCC Complex General Surgical Oncology Fellowship (2026) (https://www.mskcc.org/hcp-education-training/fellowships/complex-surgical-oncology); Holland-Frei Cancer Medicine, "The Contemporary Role of Surgical Oncology," NCBI Bookshelf (https://www.ncbi.nlm.nih.gov/books/NBK13802/); SSO, "About the Society of Surgical Oncology" (https://surgonc.org/about-the-society-of-surgical-oncology/). ↩ ↩2 ↩3 ↩4

  3. Training pathway, fellowship length (2 yrs / 96 wks), and board requirements (QE + CE, prior ABS General Surgery certification). ABS — Complex General Surgical Oncology and CGSO Fellowship Training Requirements (accessed 2026). https://www.absurgery.org/get-certified/complex-general-surgical-oncology/ ; https://www.absurgery.org/get-certified/complex-general-surgical-oncology/training-requirements/ ↩ ↩2 ↩3 ↩4

  4. Research-heavy pipeline (1–3 dedicated research years; academic-center concentration). Application and Match Rates in the CGSO Match, Annals of Surgical Oncology 2022 (PMID 35999416). https://pubmed.ncbi.nlm.nih.gov/35999416/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC9398039/ ↩ ↩2

  5. History/accreditation — ABS approved the CGSO certificate ~2011; first ABS certifications via ACGME-accredited fellowships in 2014. "ABS Certificate in CGSO: Rationale and History," Annals of Surgical Oncology / Oncohemakey reprint (2019) (https://oncohemakey.com/american-board-of-surgery-certificate-in-complex-general-surgical-oncology-rationale-and-history/); Weill Cornell, "ABS to Offer New Certificate in CGSO" (2012) (https://news.weill.cornell.edu/news/2012/05/american-board-of-surgery-to-offer-new-certificate-in-complex-general-surgical-oncology). The 2011 approval date comes from these secondary accounts rather than from an ABS page. ↩ ↩2

  6. NRMP, Results and Data: Specialties Matching Service, 2026 Appointment Year (Feb 2026), Tables 1A and 2 — Surgical Oncology (CGSO) match: 41 programs, 77 positions offered and filled (100%), 111 applicants; 56 US MD (72.7%), 6 US DO (7.8%), 4 US IMG (5.2%), 7 non-US IMG (9.1%), 4 Canadian (5.2%). https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf Corrected 2026-08-17: the Quick dashboard said ~4% DO and ~20% IMG while the body, this footnote and Table 2 all said 7.8% DO and 14.3% IMG. The DO figure was off by about a factor of two and the IMG figure by 40%, and a dashboard row is the surface a reader scans first. Both look like leftovers rather than inventions: the report's five-year trend rows put DO at 3.9% in 2025 and 4.1% in 2024, and combined IMG at 23.0% in 2023, so the row was a 2024-or-2025 DO figure sitting beside a 2023 IMG figure after the body had moved to 2026. The dashboard now matches the body. ↩ ↩2 ↩3 ↩4 ↩5

  7. Longitudinal CGSO match trends 2014–2021 (match rate 54%→74%; US-allopathic 84% vs non-US-allopathic 55% in 2021; historically ~2 unfilled positions). Application and Match Rates in the CGSO Match, Annals of Surgical Oncology 2022 (PMID 35999416). https://pubmed.ncbi.nlm.nih.gov/35999416/ Corrected 2026-08-17: the page gave the non-US-allopathic figure as ~54% in two places. The abstract reads "US allopathic graduates had higher match rates than non-US allopathic graduates but this disparity narrowed over time (84% vs. 55% in 2021; p < 0.001)." One point, no argument moves, and the 54% it was probably confused with is the 2014 overall match rate in the sentence beside it. Everything else drawn from this paper verifies exactly: "Annual match rates increased from 54% to 74%," and applicants falling from 103 to 90 against positions rising from 56 to 67. ↩ ↩2 ↩3 ↩4 ↩5

  8. Doximity 2025 Physician Compensation Report (2024 data) — General Surgery avg total comp ~$482,574 (no separate SurgOnc line); metro geography pattern. https://www.doximity.com/reports/physician-compensation-report/2025 ↩ ↩2 ↩3

  9. Medscape 2025 Surgeon report (~$434,000 General Surgery), via Barton Associates General Surgeon Salary Guide 2026 (https://www.bartonassociates.com/general-surgeon-salary-guide/). BLS OEWS, "Surgeons, All Other" (SOC 29-1249), May 2025 mean annual wage $373,930 on employment of 25,140, with a median of $414,010, a known undercount for this field. US Bureau of Labor Statistics, Occupational Employment and Wages — May 2025, Table 1 (https://www.bls.gov/news.release/archives/ocwage_05152026.htm). Updated 2026-08-18: the May 2025 release, published 2026-05-15, superseded the May 2024 mean of $371,280 carried here. Corrected 2026-08-17: the BLS row was labeled "Surgeons, except ophthalmologists" under SOC 29-1248. Neither is the Bureau's. Its physician and surgeon codes run 29-1211 through 29-1249 with no 29-1248 among them, and it publishes no occupation by that name. The $371,280 belongs to "Surgeons, All Other," SOC 29-1249, which is the residual surgical bucket left after orthopedic, pediatric and ophthalmic surgeons are broken out. The figure is unchanged; the code and the occupation name attached to it were wrong. ↩ ↩2 ↩3

  10. SurgOnc-specific estimates (broad bands, small n — treat as directional). ICGI, "What Does A Surgical Oncologist Make?" ($400k–$700k range) (2025) (https://www.icgi.org/what-does-a-surgical-oncologist-make/); Marit Health, Oncologic Surgeon Salary (~$523,000, crowdsourced) (2026) (https://www.marithealth.com/o/-/oncologic-surgeon/salary). On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. ↩

  11. Academic vs. private comp bands, starting-vs-experienced ranges (assistant prof ~$250k–$350k; senior $500k+; private up to ~$700k). Student Doctor Network, "Surgical Oncology Salary" practitioner thread (https://forums.studentdoctor.net/threads/surgical-oncology-salary.1278671/); ICGI (2025) (https://www.icgi.org/what-does-a-surgical-oncologist-make/). A forum may source pay here, because a poster reporting their own salary is first-hand about their own life — never a price, a fee, a legal requirement or a claim about an institution. Read as anecdote, not survey data. ↩ ↩2 ↩3

  12. SalaryDr — General Surgery (2026): median ~$530,000, percentile spread (10th $400k → 90th $800k), experience curve, hospital-employed avg ~$591,739, and top GS subspecialties (Breast ~$845,903, Bariatric ~$781,767, Trauma ~$624,000). https://www.salarydr.com/specialty/general-surgery SalaryDr panel size: n=128. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. ↩ ↩2 ↩3 ↩4 ↩5

  13. Academic dominance, RVU-per-hour penalty, "lowest median among GS subspecialties," 3× private-offer anecdote, no public SSO salary survey. Student Doctor Network practitioner reports. https://forums.studentdoctor.net/threads/surgical-oncology-salary.1278671/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  14. Baimas-George M, Fleischer B, Slakey D, Kandil E, Korndorffer JR, DuCoin C, "Is it All About the Money? Not All Surgical Subspecialization Leads to Higher Lifetime Revenue when Compared to General Surgery," Journal of Surgical Education 2017;74(6):e62–e66, DOI 10.1016/j.jsurg.2017.06.027, PubMed 28705484 (https://pubmed.ncbi.nlm.nih.gov/28705484/). With fellowship and no research years, breast and surgical oncology "made significantly less than general surgery (-$1,561,441, -$1,704,958), with a difference in opportunity cost equivalent to approximately 4 years of work." Read the input with the output: the study's salary base is "the Medical Group Management Association's 2015 report of average annual salaries," so a 2015 pay snapshot drives a 30-year projection this page uses four times as its strongest compensation argument. Corrected 2026-08-17: this footnote gave the byline as "Ebrahimzadeh/Ellis et al." and the journal as Annals of Surgical Oncology. Neither Ebrahimzadeh nor Ellis is an author, and the paper is in the Journal of Surgical Education. The body attributed it to "Ellis et al." as well. The load-bearing figures are exact against the abstract: $1,704,958 and about four years of work. ↩ ↩2 ↩3 ↩4

  15. MGMA Provider Compensation Data Report 2024/2025 — publishes a General Surgery: Surgical Oncology median, but the figure is paywalled; MGMA general-surgery medians run ~$450k–$550k. https://www.mgma.com/2025-provider-compensation ↩

  16. General-surgery hours (~60–66 hrs/wk) and ~84% would-choose-again, used as the closest verified proxy (no CGSO-specific dataset). SalaryDr — General Surgery Work-Life Balance (2025). https://www.salarydr.com/specialty-lifestyle/general-surgery ; SalaryDr — Surgical Oncology (no dataset yet, 2026) https://www.salarydr.com/specialty/surgical-oncology SalaryDr panel size: n=185. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. ↩

  17. Tait Shanafelt, MD — "A Career in Surgical Oncology: Finding Meaning, Balance, and Personal Satisfaction" — burnout ~28–32%, burnout as top predictor of career-choice regret, the "delayed gratification" trap, professional-personal conflict. Annals of Surgical Oncology (2008). Older data — treat as directional. https://link.springer.com/article/10.1245/s10434-007-9725-9 ↩ ↩2 ↩3 ↩4 ↩5

  18. Curative-and-palliative intent in cancer surgery. AMA Journal of Ethics, "Holding Curative and Palliative Intentions" (2021). https://journalofethics.ama-assn.org/article/holding-curative-and-palliative-intentions/2021-10 ↩

  19. Rachel Jin, MD — "Oncology grief is the price of caring deeply for patients" (KevinMD, 2026) — cumulative grief, training's failure to prepare clinicians for it. https://kevinmd.com/2026/06/oncology-grief-is-the-price-of-caring-deeply-for-patients.html ↩ ↩2

  20. "Trends in Racial and Gender Diversity Among Complex General Surgical Oncology Fellowship Trainees" — women 38.6%, URiM 8.9% of CGSO fellows (ACGME data 2013–2021, pooled), no significant increase over the period. Annals of Surgical Oncology (2023). https://link.springer.com/article/10.1245/s10434-023-13743-6 ↩ ↩2

  21. HPB training pathways (CGSO or dedicated HPB fellowship). PMC (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9350681/ ↩

Researched with AI assistance and reviewed by hand. How this site is made